How T3P Is Helping To Advance API Development

By Dr. Gagan Kukreja

Researchers face myriad challenges daily in their quest to identify, synthesize, and develop promising drug-like molecules. Dr. Gagan Kukreja, a seasoned medicinal chemist, exemplifies the tenacity and expertise required to overcome these obstacles. As the lead chemist in a discovery program for MALT1 inhibitors, Dr. Kukreja's innovative approach to selecting organic reagents early in synthesis was pivotal in expediting the journey from lead to candidate identification.

In tackling the challenge of constructing thiazolo-pyridine MALT1 inhibitors, Dr. Kukreja's team employed T3P, a versatile reagent that significantly improved reaction yields and preserved sensitive stereocenters. This strategic choice not only facilitated effective cyclization but also streamlined the scaling process, allowing the project to advance smoothly into preclinical development.

The success of this program underscored the importance of robust synthetic routes, leading to a substantial partnership with AbbVie, who secured global rights to the MALT1 inhibitors for hematological cancers. Dr. Kukreja's continued advocacy for T3P, especially Curia's superior, halogen-free version, highlights its growing significance in both pharmaceutical and agrochemical industries. This reagent's versatility and efficacy promise to drive future innovations, ensuring cost-effective and sustainable solutions across chemistry-driven sectors.

Learn more by reading the full article below.